In-Silico Drug Discovery or Computer-aided drug discovery (CADD) is a comprehensive platform for new drug research and development that integrates a variety of computer applications. It is mainly used in the early preclinical research of small molecule drug research and development, including the screening of active compounds, optimization of lead compounds, and clinical candidates in different stages of medicine. In recent years, based on the rapid development of information technology and the breakthrough in computational chemistry, more and more new drug compounds have been discovered through the use of rational drug design strategies.
With the application of artificial intelligence and cloud computing, it is foreseeable that in-silico drug discovery will play a more significant role in new drug research and development projects, improve research and development efficiency. In-silico drug discovery further reduces high research and development costs.
Global In-Silico Drug Discovery Market projected to grow at a substantial rate during the forecast period, 2020-2027. The growing emphasis on reduction in medical errors and readmission rates are major factors expected to drive the global in-silico drug discovery market in the future timeframe. Moreover, the growth in the biomarker identification market and advancements in the field of computational biology would propel the growth of the global in-silico drug discovery market size in the forthcoming periods. Additionally, the increasing number of drug discovery projects, coupled with the rapid progression in various stages of drug discovery, will augment the global in-silico drug discovery industry.
Furthermore, the main objective of in-silico drug discovery to reduce costs and late-stage attrition likely to spur the growth of in-silico drug discovery. In-silico drug discovery use in drug development helps in selecting only a potent lead molecule and may thus prevent late-stage clinical failures; thereby, a significant reduction in cost can be achieved. The upsurge in demand for in-silico drug discovery in cost-saving, time to market, speed up drug discovery and development, and in-sight knowledge of drug-receptor interactions will lead to the robust growth of the global In-Silico Drug Discovery market share in the estimated period.
In-silico drug discovery or CADD is also a vital innovation platform in the research and development of small-molecule new drugs. Compared with traditional drug discovery methods, one of the outstanding advantages of CADD is the quantitative and dynamic analysis of the interaction between small molecule compounds and their biological targets based on their three-dimensional structure, and ligands and receptors through CADD.
In-silico drug discovery technology takes only a few minutes to a few hours of direct analysis of the structure of these small-molecule compounds. It further combined with computer-simulated compound drug-like properties and drug metabolism and toxicity (ADMET), directly screen and optimize the designed small molecule compounds. It reduces the number of compounds that need to be synthesized and tested, thus significantly reduce R & D costs and accelerate the efficiency of the new drug.
Based on workflow, the global in-silico drug discovery market classified Discovery (Target Identification, Target Validation, and Lead Discovery), Preclinical Tests, and Clinical Trials. The Discovery segment predicted to gain a significant share in the in-silico drug discovery market by 2027. It is owing to the in-silico drug is used in the early preclinical development of small molecule drugs, including target identification, target validation, and lead discovery.
The clinical trials segment will drive on account of in-silico drug discovery help in continue to effective clinical trials.
Based on product, the global in-silico drug discovery market bifurcated into Software, and Service. The software segment projected to dominate the in-silico drug discovery market by 2027. It is due to software help in identify novel hits or leads against selected therapeutic targets, with the help of 2D similarity searches, 3D pharmacophore searches, and high throughput docking of databases.
The services segment will influence a lucrative growth rate during the forecast period; as a result of its help in support of drug discovery projects.
Based on the Software, the global In-Silico Drug Discovery market segregated into Molecular Modeling Drug Design Software and Pharmacophore Modeling Software. The Molecular Modeling Drug Design Software segment witnessed to dominate the market during the estimated period. It is due to the benefits of molecular modeling, such as it examines molecular conformations, molecular motions, and intermolecular interactions such as ligand-receptor complex and perform molecular dynamics at constant temperatures.
Pharmacophore Modeling Software will propel throughout the period on account of its help in elucidate key molecular and then exploit it for molecular design.
Based on end-user, the global in-silico drug discovery market categorized into Contract Research Organizations, Pharmaceutical Industry, Academic and Research Institutes, and Other (Hospitals and Other Care Facilities. Pharmaceutical Industry segment expected to gain maximum revenue by 2027 owing to the huge demand for in-silico drug discovery in drug development with minimum cost and error-free drug development.
The Contract Research Organizations segment in the forecast period will drive due to the support in drug discovery projects of any pharmaceutical, biotechnology, and medical device industries.
Based on geography, the global in-silico drug discovery market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s share in the in-silico drug discovery market by 2027. It is primarily attributed to the presence of key players in these regions coupled with huge developments of drugs for various diseases.
The Asia Pacific will drive with a significant growth rate during the projected period. It is due to rapid growth in the pharmaceutical and biopharmaceutical industry, along with the presence of less-stringent regulations for drug discovery processes.
Companies such as Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group, Collaborative Drug Discovery Inc., Dassault System (Biovia), Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC. , Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schrödinger, LLC, Selvita, Simulation Plus, and WuXi AppTec are the key players in the Global In-Silico Drug Discovery Market.
By Software Type